Navigation Links
Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
Date:3/7/2012

LA JOLLA, CA - Scientific advances at The Scripps Research Institute have led to a new drug Surfaxin (lucinactant), approved today by the U.S. Food and Drug Administration (FDA) to treat infant respiratory distress syndrome.

"I am excited that our scientific findings will help save lives," said Charles Cochrane, MD, professor emeritus at Scripps Research. "Many years of work in our basic research laboratory at The Scripps Research Institute made this landmark development possible."

Respiratory distress syndrome (also known as neonatal respiratory distress syndrome) is a life-threatening condition affecting pre-term infants. The more premature an infant is, the more likely he or she is to suffer from it and die.

The condition occurs when infants are born prior to the time when natural surfactant is made in their lungs. Surfactant is a liquid that coats the inside of the lungs, helping to keep the air sacs open and making normal breathing possible. Without enough surfactant, the lungs collapse and the body can be starved of oxygen.

In addition to mechanical ventilation, current treatments for pre-term infants involve using surfactants derived from chopped cow or pig lungs. However, animal-derived surfactants are expensive, contain material that can be injurious to the lungs, and cannot be produced in quantities sufficient to treat pre-term infants worldwide. In addition, animal-derived surfactants can only be used once since they cause an immune reaction; in contrast, the new synthetic surfactant is not immunogenic.

The Cochrane lab first created a synthetic version of surfactant in the 1990s, mimicking a natural peptide known as Surfactant Protein B; the inventors of the technology are Cochrane and Susan Revak. After this formative work at Scripps Research, the therapy was developed by Discovery Labs of Warrington, PA, which oversaw the three phases of clinical trials required by the FDA. These clinic trials pro
'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
Scripps Research Institute
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Scripps research team solves structure of beneficial virus
2. Scripps research team sheds light on immune system suppression
3. Scripps Florida scientists awarded $1.5M to fight major water and food parasites
4. Scripps research scientists identify compounds for stem-cell production from adult cells
5. Scripps research scientists identify blood component that turns bacteria virulent
6. Scripps research team defines new painkilling chemical pathway
7. Dolphin population stunted by fishing activities, Scripps/NOAA study finds
8. Scripps Research scientists shed light on how DNA is unwound so that its code can be read
9. Scripps scientists develop first examples of RNA that replicates itself indefinitely
10. Scripps scientists create first crystal structure of an intermediate particle in virus assembly
11. Historical photographs expose decline in Floridas reef fish, new Scripps study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
(Date:12/10/2014)... , December 9, 2014 ... ITN,s BCARD Platform   ... enterprise meeting scheduling solutions for business-to-business (B2B) events, ... world leader in mobile near-field communication (NFC), Bluetooth ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a leading ... that its DigitalPersona ® Pro Enterprise software ... been deployed throughout First Bank branch locations in ... South Carolina and Virginia. First Bank, a ... Southern Pines, North Carolina , selected the ...
(Date:11/21/2014)... According to a new market ... RFID, Access Control, Intrusion Detection, Parking Management, Under Vehicle ... Service Geography - Global Forecasts to 2020", published by ... be around $25 Billion in 2014 and is expected ... CAGR of 8.69%. Browse 116 market data ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... COLUMBUS, Ohio The wasting disease associated with some ... also cause significant damage to the heart, new research ... muscle wasting and dramatic weight loss, was believed to ... showed that the condition reduces heart function and changes ...
... pathogens that were once thought to be very different ... are not only similar but also suggest that in ... according to a review published this week in the ... used by bacterial and fungal species to promote genetic ...
... The National Institute of General Medical Sciences has awarded ... for a study titled "Expression Genetics in Drug Therapy." The ... and reduce the number of adverse drug reactions among patients ... State as a member of a nationwide Pharmacogenomics Research Network ...
Cached Biology News:Muscle wasting in cancer does not spare the heart 2Muscle wasting in cancer does not spare the heart 3Linking microbial sex and virulence 2$9.1 million grant to improve drug therapy using gene profiles 2$9.1 million grant to improve drug therapy using gene profiles 3
(Date:12/17/2014)... December 16, 2014 “Never say, ... Philipps- Universität Marburg’s Department of Physics, advises young ... the newly released SPIE Women in Optics ... too shy to ask questions.” , In the ... and mathematics) occupations ranging from university professor and ...
(Date:12/17/2014)... December 17, 2014 Xeno Diagnostics ... following its most recent COLA inspection. Xeno has ... a national healthcare accreditation organization. Accreditation is earned ... quality in day-to-day operations, demonstrate continued accuracy in ... rigorous on-site laboratory survey. , While ...
(Date:12/17/2014)... Md. , Dec. 17, 2014 CASI ... company dedicated to the acquisition, development and commercialization of ... for the global market with a primary commercial focus ... it has been granted a Type C meeting with ... the meeting will be held in February 2015.  During ...
(Date:12/15/2014)... DIEGO , Dec. 15, 2014 ... three-dimensional biology company focused on delivering breakthrough 3D ... the industry and collaborators of its exVive3D TM ... made widely available in full commercial release on ... the field, resulting in several awards for innovation. ...
Breaking Biology Technology:Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3
... SCOTTSDALE, Ariz., Sept. 14 CHS, an inVentiv,Health company ... U.S. Department,of Defense as a recipient of the 2007 ... by the National Committee of Employer,Support of the National ... America,s employers who provide support to their employees,serving in ...
... SOUTH SAN FRANCISCO, Calif., Sept. 14 ,Exelixis, ... the company has,submitted a comprehensive data report relating ... 2007, GSK requested to initiate its review of,XL880 ... the,product development and commercialization agreement between the two,companies. ...
... (Nasdaq: HALO ), a biopharmaceutical company developing and,commercializing ... Lim, MD, Halozyme,s President and Chief Executive Officer,will present ... be held at,the Grand Hyatt Hotel in New York ... (6:00 a.m. Pacific time). Interested parties can access ...
Cached Biology Technology:CHS Receives Prestigious Honor from Department of Defense 2CHS Receives Prestigious Honor from Department of Defense 3Exelixis Submits XL880 Diligence Report to GlaxoSmithKline 2Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference 2
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap. (2/sp, 20/ca) Packaging: 2 / pack, 20 /...
... Display Vector is specifically designed to target ... of Saccharomyces cerevisiae. Displayed proteins can be ... known or putative ligands. pYD1 uses the ... two domains, Aga1 and Aga2, to display ...
... are used for heterologous protein expression in the ... S2 cell line was derived from a primary ... Drosophila melanogaster embryos (1). This versatile ... CO2 and is easily adapted to suspension culture. ...
ACS Reagent Grade C 19 H 14 O 5 S Formula Weight: 354.38 PRODUCT SPECIFICATIONS Form: Rust/red crystalline powder Clarity of Solution: Passes test Visual Transition Interval: pH 6.8 - Yellow pH 8.2...
Biology Products: